Semaglutide is not a shortcut to weight loss: Experts Advise

With Semaglutide Indian versions hitting the market as the global weight-loss and diabetes drug moves off patent, leading cardiology, endocrinology, and diabetology experts from Pune and Mumbai have issued a firm warning: Semaglutide alone is not a shortcut to weight loss.

Doctors made it clear that while the drug is clinically proven to support weight loss and blood sugar control, its benefits only come when paired with a structured plan of balanced eating, strength training, and regular exercise. Experts emphasized that a valid prescription, careful patient evaluation, and ongoing medical monitoring are essential to safe treatment.

Specialists noted a troubling trend of patients seeking Semaglutide India without meeting the eligibility criteria. They stressed misuse could derail results, and that any treatment must be individualized. Without proper nutrition and strength training, patients risk losing muscle instead of fat.

Adherence to treatment plans is a major hurdle, doctors said. Success depends on sticking to dosing schedules, proper dose escalation, and frequent follow?ups to manage side effects like nausea and early satiety. High dropout rates, clinicians added, underscore the need for specialist oversight and thorough patient counseling.

Also Read: Role of Wellness in Corporate & Community Health

Experts also drew a clear line between the original biologic drug and newer generics. The innovator version of Semaglutide is supported by nearly 50 clinical trials and more than a decade of global use in over 25 million patients, evidence generics have yet to match.

Dr. Sanjay Agarwal – Diabetologist & Internal Medicine: "Obesity is a widespread issue in India, with 70% of the population affected in some form. While traditional methods like diet and exercise offered modest weight loss, they were insufficient for individuals with a BMI above 30. 

"The advent of semaglutide provides a promising and affordable solution to bridge the treatment gap. By reducing weight, we can significantly lower the risk of chronic diseases such as diabetes, hypertension, heart disease, and cancer."

Dr Jagdish Hiremath – Cardiologist: "Obesity is a major risk factor for heart disease, and its management is critical in preventing cardiovascular issues. For patients without heart disease, addressing obesity early can help prevent future complications. In those with existing heart conditions, weight loss through treatments like semaglutide can help mitigate further risks. 

Dr Rajiv Kovil – Diabetologist: "Semaglutide marks a significant breakthrough in our ability to address the root cause of obesity and diabetes—the wrong deposition of fat in organs like the liver, pancreas, and kidneys. With each percentage of fat reduction, we see a meaningful modification in disease outcomes. 

Dr.Vaishali Deshmukh – Senior Endocrinologist: "Obesity is not merely a lifestyle issue but a disease affecting multiple organs in the body. We must focus on adipocyte or fat health similar to any organ health and metabolic evaluation must be done along with BMI and body composition assessment to understand the true impact of obesity.